Results 81 to 90 of about 77,603,174 (247)

Long COVID-19—it's not over until? [PDF]

open access: yesClinical Microbiology and Infection, 2021
Yelin, Dana   +4 more
openaire   +2 more sources

Dual pKa Lipid Nanoparticles for Lung‐tropic mRNA Delivery and pH‐Programmed Endosomal Escape

open access: yesAdvanced Science, EarlyView.
Lipid nanoparticles’ bottleneck lies in low endosomal escape efficiency and liver‐dominant delivery after intravenous administration. To overcome these limitations, we present a stepwise pH‐programmed lipid nanoparticle system enabled by our newly synthesized ionizable lipid.
Seong Gi Lim   +12 more
wiley   +1 more source

Hyper‐Intense Tumor Peripheral Accumulation of Antibody‐Conjugated Iron Oxide Nanoparticles can Enable Breast Cancer Detection by Magnetic Particle Imaging

open access: yesAdvanced Science, EarlyView.
Tumor‐associated inflammation retains antibody‐targeted or non‐specific antibody conjugated nanoparticles within the tumor microenvironment. Magnetic Particle Imaging (MPI) enables non‐invasive detection and differentiation of tumors from other organs, owing to higher nanoparticle retention by inflammatory cells in the tumor periphery.
Preethi Korangath   +9 more
wiley   +1 more source

Anti-interferon α-antibodies in pediatric patients with COVID-19 and long COVID

open access: yes
Introduction The involvement of neutralizing antibodies against type I interferon (IFN-I) in the development of severe coronavirus disease 2019 (COVID-19) in adult patients has been well documented.
Tetiana Kosovska   +3 more
core   +1 more source

OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD

open access: yesAdvanced Science, EarlyView.
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li   +11 more
wiley   +1 more source

A Dual‐Membrane Biomimetic Nanoplatform Enables Triple‐Modal Therapy Against SARS‐CoV‐2 Through Viral Decoy, Inflammation Neutralizing, and Intracellular RNAi

open access: yesAdvanced Science, EarlyView.
[A&T]MLN is a triple‐modal nanoplatform with siRNA‐loaded LN coated with hybrid ACE2/macrophage membrane. It blocks viral entry, neutralizes IL‐6/IL‐1β/TNF‐α, and delivers siRNA to suppress viral replication. In a murine lung injury model, it attenuates inflammation, offering a multi‐pronged strategy against SARS‐CoV‐2 variants and hyperinflammation ...
Hui Li   +19 more
wiley   +1 more source

Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) \u2014 United States, February 12\u2013March 16, 2020

open access: yes
What is already known about this topic?: Early data from China suggest that a majority of coronavirus disease 2019 (COVID-19) deaths have occurred among adults aged 6560 years and among persons with serious underlying health conditions.What is added by ...

core  

Intelligent Programmable Membrane Nanosponge for Early Virus Blocking

open access: yesAdvanced Science, EarlyView.
A smart programmable nanosponge (ACNPs) displays high‐density viral receptors on its membrane and encapsulates fusion inhibitors to capture virions at the infection source through competitive binding and blocks their entry through protease inhibition for ultra‐early cascade interception. This modular, mucus‐penetrating platform shifts antiviral defence
Ze Chen   +17 more
wiley   +1 more source

COVID-19: The Long Tail

open access: yesJournal of the American College of Radiology, 2020
openaire   +3 more sources

Home - About - Disclaimer - Privacy